| Ytd | -37.89% | |
| 1y | -45.50% |
| Open | 2.36 | Prev Close | 2.36 | Low | 2.17 | High | 2.36 | Mkt Cap | 239.31M |
| Vol | 1.97M | Avg Vol | 1.76M | EPS | -0.17 | P/E | N/A | Forward P/E | -3.35 |
| Beta | 1.02 | Short Ratio | 7.72 | Inst. Own | 106.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 3.21 | 200-d Avg | 3.52 | 1yr Est | 40.93 |
RCKT News
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated com
Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or
Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neut
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology compa
Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and m
Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.
Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex ros
Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and m
Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and annou